[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Immuneering Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::78703821.png) @Immuneering Immuneering Corp

Immuneering Corp posts on X about $imrx, live from, promising, vienna the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::78703821/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:interactions.svg)

- X Week XXXXX +67%
- X Month XXXXX +49%
- X Months XXXXX +358%
- X Year XXXXX +1,780%

### Mentions: X [#](/creator/twitter::78703821/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:posts_active.svg)

- X Week X +400%
- X Month X +167%
- X Months XX +100%
- X Year XX +500%

### Followers: XXX [#](/creator/twitter::78703821/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:followers.svg)

- X Month XXX +19%
- X Months XXX +39%
- X Year XXX +48%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::78703821/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::78703821/influence)
---

**Social category influence**
[exchanges](/list/exchanges)  XXXXX% [travel destinations](/list/travel-destinations)  XXXXX% [stocks](/list/stocks)  XXXXX%

**Social topic influence**
[$imrx](/topic/$imrx) #10, [live from](/topic/live-from) 14.29%, [promising](/topic/promising) 14.29%, [vienna](/topic/vienna) 14.29%, [momentum](/topic/momentum) 14.29%, [$200m](/topic/$200m) 14.29%, [$25m](/topic/$25m) 14.29%, [sanofi](/topic/sanofi) XXXXX%

**Top accounts mentioned or mentioned by**
[@biotechtv](/creator/undefined) [@sdbjnews](/creator/undefined) [@letswinpc](/creator/undefined) [@targetedonc](/creator/undefined) [@benzeskind](/creator/undefined) [@bradloncar](/creator/undefined) [@immuneerings](/creator/undefined) [@garbagealpha](/creator/undefined) [@mainz058](/creator/undefined) [@kapstahoon](/creator/undefined) [@skipperdoodle3](/creator/undefined) [@michaeljanicki](/creator/undefined)

**Top assets mentioned**
[Sanofi (SNY)](/topic/sanofi)
### Top Social Posts [#](/creator/twitter::78703821/posts)
---
Top posts by engagements in the last XX hours

"#PancreaticCancer is one of the most challenging cancers to treat. At $IMRX were encouraged by our clinical data featured by @LetsWinPC highlighting the potential of our investigational therapy atebimetinib to help address this urgent unmet need"  
[X Link](https://x.com/Immuneering/status/1975954410581660023) [@Immuneering](/creator/x/Immuneering) 2025-10-08T16:00Z XXX followers, XXX engagements


"Our clinical data featured in @TargetedOnc highlight the potential of our investigational therapy atebimetinib in combination with chemotherapy to help address pancreatic cancer an area of urgent unmet need"  
[X Link](https://x.com/Immuneering/status/1976316772262244554) [@Immuneering](/creator/x/Immuneering) 2025-10-09T16:00Z XXX followers, XXX engagements


"$IMRX and @BenZeskind were honored to join @bradloncar and @BiotechTV live from the NYSE to discuss our latest progress in oncology including promising pancreatic cancer data and our deep cyclic inhibitors. Watch the full video here:"  
[X Link](https://x.com/Immuneering/status/1976672755870564604) [@Immuneering](/creator/x/Immuneering) 2025-10-10T15:34Z XXX followers, XXX engagements


"Meet us in Vienna during #BIOEurope taking place Nov 3-5 Our CBO E.B. Brakewood will be onsite to meet with global business leaders and industry experts in the biotech & pharma fields. Learn more about $IMRX and our pipeline:"  
[X Link](https://x.com/Immuneering/status/1977766482768519636) [@Immuneering](/creator/x/Immuneering) 2025-10-13T16:00Z XXX followers, XXX engagements


"ICYMI: $IMRX ended Sept. with strong momentum: XX% 9-month survival in 1L pancreatic cancer (atebimetinib + mGnP) and a $200M financing including $25M from Sanofi. Webcast replay:"  
[X Link](https://x.com/Immuneering/status/1978481083717927224) [@Immuneering](/creator/x/Immuneering) 2025-10-15T15:20Z XXX followers, XXX engagements